Zika Vaccine Could Actually be Profitable, Companies Say : nbcnews

referring to nbcnews

Zika Vaccine Could Actually be Profitable, Companies Say

Zika Vaccine Could Actually be Profitable, Companies Say

The race to find protection against the Zika virus is fueled by something often missing from tropical disease research: the potential for big profit.The prospect of a blockbuster vaccine against a mosquito-borne virus has accelerated the pace of development and attracted the interest of big drugmakers, including Sanofi, GlaxoSmithKline Plc and Takeda Pharmaceuticals.Play FacebookTwitterGoogle PlusEmbed Zika Transmission Zones Expand in Miami Beach 1:31 autoplay autoplay Copy this code to your website or blogAlthough Zika infections are mild or asymptomatic in most people, demand for a vaccine is expected to be strong because it can cause devastating birth defects, pharmaceutical executives and disease experts said.


as well executivebiz

NIH Arm Hands Down Zika Vaccine Development Grant

NIH Arm Hands Down Zika Vaccine Development Grant

ExecutiveBizExecutiveBiz is dedicated to covering the government contracting sector from the perspective of the executive.Your Information will never be shared with any third party.


in the same way webmd

Top Zika Vaccine Candidate Closer to Field Testing

Top Zika Vaccine Candidate Closer to Field Testing

Top Zika Vaccine Candidate Closer to Field TestingDNA-based shot should be ready for larger groups of people in case of outbreaks next year, U.S. health officials sayWebMD News from HealthDayBy Dennis ThompsonHealthDay ReporterMONDAY, Oct. 3, 2016 (HealthDay News) -- The leading Zika vaccine candidate should be ready for field testing should new outbreaks occur next year, U.S. health officials announced Monday.Over the weekend, researchers finished recruitment of the 80 volunteers needed for phase 1 trials of a DNA vaccine to protect against Zika, said Dr. Anthony Fauci, director of the U.S. National Institute for Allergy and Infectious Diseases (NIAID).In a Phase 1 trial, a drug or vaccine is tested in a small group, largely for safety.